Your browser doesn't support javascript.
loading
Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma.
Farah, J; Sayah, R; Martinetti, F; Donadille, L; Lacoste, V; Hérault, J; Delacroix, S; Nauraye, C; Vabre, I; Lee, C; Bolch, W E; Clairand, I.
Afiliação
  • Farah J; Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France jad.farah@irsn.fr.
  • Sayah R; Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France.
  • Martinetti F; Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France.
  • Donadille L; Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France.
  • Lacoste V; Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France.
  • Hérault J; Centre Antoine Lacassagne (CAL) - Cyclotron biomédical, 227 avenue de la Lanterne, 06200 Nice, France.
  • Delacroix S; Institut Curie - Centre de Protonthérapie d'Orsay (ICPO) - Campus universitaire bâtiment 101, 91898 Orsay, France.
  • Nauraye C; Institut Curie - Centre de Protonthérapie d'Orsay (ICPO) - Campus universitaire bâtiment 101, 91898 Orsay, France.
  • Vabre I; Institut de physique nucléaire (IPN), 91406 Orsay Cedex, France.
  • Lee C; Division of Cancer Epidemiology and Genetics, National Institute of Health, Bethesda, MD 20852, USA.
  • Bolch WE; Departments of Nuclear & Radiological and Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
  • Clairand I; Institut de Radioprotection et de Sûreté Nucléaire (IRSN) - PRP-HOM/SDE - BP17, 92262 Fontenay-aux-Roses Cedex, France.
Radiat Prot Dosimetry ; 161(1-4): 363-7, 2014 Oct.
Article em En | MEDLINE | ID: mdl-24222710
ABSTRACT
Monte Carlo simulations were used to assess secondary neutron doses received by patients treated with proton therapy for ocular melanoma and craniopharyngioma. MCNPX calculations of out-of-field doses were done for ∼20 different organs considering realistic treatment plans and using computational phantoms representative of an adult male individual. Simulations showed higher secondary neutron doses for intracranial treatments, ∼14 mGy to the salivary glands, when compared with ocular treatments, ∼0.6 mGy to the non-treated eye. This secondary dose increase is mainly due to the higher proton beam energy (178 vs. 75 MeV) as well as to the impact of the different beam parameters (modulation, collimation, field size etc.). Moreover, when compared with published data, the assessed secondary neutron doses showed similar trends, but sometimes with sensitive differences. This confirms secondary neutrons to be directly dependent on beam energy, modulation technique, treatment configuration and methodology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_financiamento_saude Assunto principal: Craniofaringioma / Neoplasias Oculares / Terapia com Prótons / Melanoma / Nêutrons Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Radiat Prot Dosimetry Ano de publicação: 2014 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_financiamento_saude Assunto principal: Craniofaringioma / Neoplasias Oculares / Terapia com Prótons / Melanoma / Nêutrons Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Radiat Prot Dosimetry Ano de publicação: 2014 Tipo de documento: Article País de afiliação: França
...